Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | CALGB/SWOG 80702: celecoxib and FOLFOX in stage III colon cancer

Charles Fuchs • 22 May 2020
ASCO 2020
Colorectal Cancer
CALGB/SWOG 80702

Charles Fuchs, MD, MPH, Yale Cancer Center, New Haven, CT, discusses the results from the CALGB/SWOG 80702 study (NCT01150045) which aimed to determine the effect of celecoxib, a COX2 inhibitor, in patients with stage III colon cancer. Despite not resulting in statistically significant improvements in disease free survival, there is still the posibility that aspirin or aspirin-like compounds can have therapeutic value for colon cancer patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Charles Fuchs

Updates from the Phase III KEYNOTE-061 trial
6:57
Updates from the Phase III KEYNOTE-061 trial
Charles Fuchs • 22 May 2020

Related Videos

POLE mutations as predictive biomarkers for immunotherapy in GI cancers
4:30
POLE mutations as predictive biomarkers for immunotherapy in GI cancers
Umair Mahmood • 16 Apr 2026
BATTMAN trial: botensilimab and balstilimab in MSS mCRC
1:14
BATTMAN trial: botensilimab and balstilimab in MSS mCRC
Benjamin Schlechter • 2 Jul 2026
Ablative treatment for colorectal liver metastases with curative intent: insights from CIEMAR
1:19
Ablative treatment for colorectal liver metastases with curative intent: insights from CIEMAR
Dirk Arnold • 10 Jul 2026
DEL-LIVER: percutaneous hepatic perfusion with melphalan for liver-dominant refractory mCRC
1:38
DEL-LIVER: percutaneous hepatic perfusion with melphalan for liver-dominant refractory mCRC
Dirk Arnold • 10 Jul 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals